PSI-6130

PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark. Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called NS5B. PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark. Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called NS5B. PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128. R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.